Evidence map›Paper›PMID 40168061›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025

Fibulin-4 and latent-transforming growth factor beta-binding protein-4 interactions with syndecan-2 and syndecan-3 are required for elastogenesis.

Hana Hakami, Neha E H Dinesh, Valentin Nelea, Nathalie Lamarche-Vane, Sylvie Ricard-Blum, Dieter P Reinhardt

Abstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Fibulin-4 and latent-transforming growth factor beta-binding protein-4 interactions with syndecan-2 and syndecan-3 are required for elastogenesis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hana HakamiFaculty of Medicine and Health Sciences, Department of Anatomy and Cell Biology, McGill University, Montréal, Quebec, Canada.
Neha E H DineshFaculty of Medicine and Health Sciences, Department of Anatomy and Cell Biology, McGill University, Montréal, Quebec, Canada.
Valentin NeleaFaculty of Medicine and Health Sciences, Department of Anatomy and Cell Biology, McGill University, Montréal, Quebec, Canada.
Nathalie Lamarche-VaneFaculty of Medicine and Health Sciences, Department of Anatomy and Cell Biology, McGill University, Montréal, Quebec, Canada.
Sylvie Ricard-BlumInstitute of Molecular and Supramolecular Chemistry and Biochemistry (ICBMS), UMR 5246, CNRS, University Claude Bernard Lyon 1, Villeurbanne, France.ORCID https://orcid.org/0000-0001-9263-1851
Dieter P ReinhardtFaculty of Medicine and Health Sciences, Department of Anatomy and Cell Biology, McGill University, Montréal, Quebec, Canada.ORCID https://orcid.org/0000-0001-6535-9872

Funding

Canadian Government|Natural Sciences and Engineering Research Council of Canada (NSERC) RGPIN-2022-05045Embassy of the Kingdom of Saudi Arabia in CanadaFRQ|Fonds de Recherche du Québec - Santé (FRQS) 291220Genetic Aortic Disorders Association CanadaKing Saud University (KSU)
6 · The paper itself

Abstract

Elastogenesis is a cell surface-located hierarchical process that requires the core components tropoelastin and fibrillins and several accessory proteins, including fibulin-4 (FBLN4) and latent TGF-β binding protein-4 (LTBP4). FBLN4 and LTBP4 interact with cells, but their cell receptors and associated molecular elastogenic mechanisms remain unknown. Primary skin fibroblasts and several vascular smooth muscle cells bound strongly to FBLN4 multimers and LTBP4 monomers. We identified two cell interaction epitopes on FBLN4 located in cbEGF2-3 and the C-terminal domain, whereas FBLN4 multimerization sites were mapped to cbEGF4-5 and the C-terminal domain. We also determined a novel cell interaction site in the N-terminal half of LTBP4. Cell binding to FBLN4 and LTBP4 was strongly inhibited in the presence of heparin, heparan sulfate, or after enzymatic removal of heparan sulfate, suggesting heparan sulfate proteoglycans as relevant cell surface receptors. siRNA knockdown experiments identified syndecan (SDC)2 and SDC3 as cell receptors for FBNL4 and SDC3 for LTBP4. Direct protein interactions between FBLN4 and the recombinant ectodomains of SDC2 and SDC3, and between LTBP4 and SDC3 validated these results. Interaction of the elastogenic cells with FBLN4 and LTBP4 enhanced elastogenesis, whereas SDC2 and/or SDC3 knockdowns led to reduced elastic fiber formation. The cell interactions with FBLN4 and LTBP4 significantly enhanced focal adhesion formation, induced cell contraction, and led to activation of focal adhesion kinase (FAK), Erk1/2, and RhoA. Pharmacological inhibition of these effectors markedly attenuated elastic fiber formation, and siRNA knockdown of SDC2 and SDC3 led to reduced levels of pFAK, pERK, and active RhoA. Together, these data demonstrate that FBLN4 and LTBP4 cell interactions through SDC2 and SDC3 promote elastogenesis by enhancing focal adhesion formation, leading to cell contractility through FAK, Erk1/2, and RhoA activation, underscoring the significance of these pathways in elastogenesis.

Indexed as

Elastic TissueExtracellular Matrix ProteinsLatent TGF-beta Binding ProteinsSyndecan-2Syndecan-3Cells, CulturedFibroblastsHumansMuscle, Smooth, VascularMyocytes, Smooth MuscleProtein BindingEFEMP2 protein, humanExtracellular Matrix ProteinsLatent TGF-beta Binding ProteinsLTBP4 protein, humanSDC2 protein, humanSyndecan-2Syndecan-3cell contractioncell interactionselastic fibersfibulin‐4focal adhesionlatent TGF‐β binding protein‐4syndecan‐2syndecan‐3

Identifiers

PMID40168061
PMCPMC11960800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.